Swiss National Bank Erasca, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Erasca, Inc. stock. As of the latest transaction made, Swiss National Bank holds 329,700 shares of ERAS stock, worth $837,438. This represents 0.0% of its overall portfolio holdings.

Number of Shares

329,700

Holding current value

$837,438

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$2.17 - $3.28 $715,449 - $1.08 Million	329,700 New	329,700 $900,000
Q4 2023 Feb 06, 2024	SELL	$1.67 - $2.49 $55,945 - $83,415	-33,500 Reduced 18.38%	148,800 $316,000
Q3 2023 Nov 08, 2023	BUY	$1.97 - $2.91 $36,248 - $53,544	18,400 Added 11.23%	182,300 $359,000
Q2 2023 Aug 09, 2023	BUY	$2.57 - $3.3 $39,321 - $50,490	15,300 Added 10.3%	163,900 $452,000
Q1 2023 May 10, 2023	SELL	$2.74 - $4.44 $34,524 - $55,944	-12,600 Reduced 7.82%	148,600 $447,000
Q4 2022 Feb 08, 2023	BUY	$3.89 - $8.57 $348,544 - $767,872	89,600 Added 125.14%	161,200 $694,000
Q2 2022 Aug 09, 2022	BUY	$4.58 - $8.72 $65,036 - $123,824	14,200 Added 24.74%	71,600 $399,000
Q1 2022 May 09, 2022	BUY	$8.6 - $15.48 $34,400 - $61,920	4,000 Added 7.49%	57,400 $494,000
Q4 2021 Feb 08, 2022	BUY	$12.51 - $22.75 $668,034 - $1.21 Million	53,400 New	53,400 $832,000

Others Institutions Holding ERAS

# of Institutions

140

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

Frazier Life Sciences Management, L.P. Menlo Park, CA

19.4M
Shares

$49.3 Million
2.85% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

16.8M
Shares

$42.8 Million
0.03% of portfolio
Vr Adviser, LLC New York, NY

16.2M
Shares

$41.2 Million
4.58% of portfolio
Suvretta Capital Management, LLC New York, NY

13.8M
Shares

$35 Million
1.48% of portfolio
Vanguard Group Inc Valley Forge, PA

13.3M
Shares

$33.8 Million
0.0% of portfolio

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account